Building the controllable payload layer for precision oncology.
GenLumina is a preclinical oncology platform company developing a light-activated intracellular payload designed for targeted therapies. We build the core payload technology, activation know-how and IP so that multiple therapeutic programmes can be developed around different targeting biology.
Patient impact
Develop a more controllable treatment approach intended to reduce unnecessary exposure of healthy tissue.
Independent activation control
Molecular targeting determines which cells the construct reaches; light provides a separate spatial activation switch.
Built for multiple partners
Develop and retain the core platform while building separately agreed programmes around partner-owned antibodies, peptides or ligands.
Different disciplines. One shared platform mission.
GenLumina combines fundamental science, translational oncology, product development and partnering expertise to turn a controllable payload concept into a repeatable platform that can support multiple therapeutic programmes.
DNA nanotechnology
The platform builds on research in nanoscale positioning, drug delivery and silver-cluster DNA technology.
From concept to evidence
GenLumina connects laboratory development with preclinical oncology, safety, efficacy, manufacturing and regulatory preparation.
Build the reusable core
Internal programmes generate evidence around the payload, conjugation and controlled activation rather than locking the company into one target or indication.
Expand through partners
Pharma and biotech partners can contribute targeting biology, development capabilities and indication expertise for separately defined programmes.
Build the platform. Validate with partners. License programmes.
GenLumina does not need to independently develop every oncology product to market. The company builds and protects the underlying payload platform, generates transferable evidence through internal programmes and works with pharmaceutical partners to create separately defined therapeutic programmes.
Build platform evidence
Internal programmes test conjugation, targeting, intracellular delivery, light activation, safety and tumor-cell killing.
Bring targeting biology
A pharma or biotech partner can bring an antibody, peptide or ligand relevant to its own pipeline and indication priorities.
Decide on evidence
GenLumina and the partner evaluate the combination against predefined technical and biological criteria.
License successful programmes
A successful PoC can progress through an agreed option toward separately negotiated rights for a defined indication and geographic territory.
This allows the same controllable payload technology to support multiple partners, targeting molecules and tumor indications without transferring the entire platform to a single programme.
Science, technology and translation.
The founders combine scientific expertise with the entrepreneurial capability required to develop, protect and partner an emerging oncology platform.
Donny de Bruin, PhD
Founding Partner & Chief Scientific OfficerDonny de Bruin is a biophysicist specializing in DNA nanotechnology, with a focus on theragnostic applications. He has over a decade of experience in DNA for biosensing, nanoscale positioning and drug delivery. His research at Leiden University laid the foundation for GenLumina’s technology.
Prof. Dr. D. Bouwmeester
Founding Partner & Patent OfficerProf. Dr. Bouwmeester, affiliated with Leiden University and UCSB, is a physicist and recipient of the Spinoza Award. With around 200 publications, his work spans quantum optics and biophysics. He has more than 15 years of experience in silver-cluster DNA technology and its potential therapeutic applications.
Gerco Kanbier
Founding Partner & Managing DirectorGerco Kanbier has two decades of entrepreneurial experience in technology, cybersecurity and product development. His focus at GenLumina is company development, financing, strategic partnering and translating an emerging scientific platform into a scalable business.
Experience for the next stage.
Independent expertise in preclinical oncology development and biotech transactions supports GenLumina as the platform moves toward broader validation, partnering and licensing.
Anja Slikkerveer
Pre-Clinical Drug Developer Oncology · Advisory BoardSenior preclinical oncology drug developer with expertise in toxicology and metal-based therapies.
Anton Mat
Business Development · Advisory BoardSenior business developer and dealmaker in the biotech industry with more than 25 years of experience.
Bring your targeting biology.
Pharma and biotech partners can start with a focused partner-specific proof-of-concept. GenLumina provides the controllable payload, enabling know-how and platform IP; a successful programme can create the option to advance through a separately agreed licence.